World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT00695916
Date of registration: 10/06/2008
Prospective Registration: Yes
Primary sponsor: Stanford University
Public title: MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery
Scientific title: Randomized Trial of Breast MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery
Date of first enrolment: September 2008
Target sample size: 0
Recruitment status: Withdrawn
URL:  https://clinicaltrials.gov/show/NCT00695916
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).  
Phase:  Phase 3
Countries of recruitment
United States
Contacts
Name:     Frederick M. Dirbas
Address: 
Telephone:
Email:
Affiliation:  Stanford University
Key inclusion & exclusion criteria

Inclusion Criteria:

- DCIS less than 5 cm. T1/T2 invasive breast cancer. Patient is a suitable candidate for
breast conservation and wishes this as the primary clinical approach

- No breast MRI within the past year. Prior core biopsy, but no prior excision allowed.
Patient has completed conventional imaging workup with mammography ultrasound as
indicated and there is no clinical indication for breast MRI.

- Women with age >= 18. No ethnic restrictions.

- No life expectancy restrictions.

- Performance status not a factor.

- No requirements for organ or marrow function.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patient is unable to complete a breast MRI due to such factors as hardware and
claustrophobia.

- No limitations as to other investigational agents. Patients who have received
neoadjuvant chemotherapy will not be included in the study due to the limitations of
MRI interpretation after neoadjuvant chemotherapy and because this represents a
distinct scenario for interpretation of breast MRI in comparison with untreated
patients.

- There are no comorbidities that would preclude entry into the study unless the patient
is unable to lay still for breast MRI scanning.

- There are fewer reactions to MRI contrast media, but if there is such a history, the
patient will be excluded from consideration.

- There are no exclusion criteria based on concomitant medications.

- There are no other agent specific exclusion criteria.

- Pregnancy is considered a contraindication given the uncertain effects of breast MRI
on the fetus.

- Cancer survivors are candidates for the study unless the patient has a prior
ipsilateral breast tumor.



Age minimum: 18 Years
Age maximum: N/A
Gender: Female
Health Condition(s) or Problem(s) studied
Breast Cancer
Intervention(s)
Procedure: Breast MRI
Primary Outcome(s)
To determine whether pre-lumpectomy breast MRI reduces the frequency of repeat lumpectomy in women with DCIS < 5 cm or T1 or T2 invasive breast cancer
Secondary Outcome(s)
To determine how often MRI will miss occult DCIS or invasive cancer subsequently detected on surgical pathology
To determine the frequency with which breast MRI changes the surgical plan
To measure the degree and extent to which preoperative MRI lengthens the time required to deliver care
To measure whether preoperative MRI is associated with enhanced postoperative cosmesis
To determine the frequency of false positive MRI findings requiring biopsy
To measure whether preoperative MRI alters cost of care
To measure whether MRI decreases the risk of ipsilateral breast tumor recurrence
To measure whether preoperative MRI increases the rate of patient directed ("unnecessary") mastectomy
To measure disease-free survival without/with preoperative breast MRI
To measure whether MRI reduces the frequency of repeat lumpectomy to a greater extent in women with mammographically dense vs fatty breasts
To determine how often MRI will detect occult multifocal or multicentric disease
To measure overall survival without/with preoperative MRI
Secondary ID(s)
98272
6125
BRSNSTU0025
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history